Kestra Medical Technologies, Ltd. (KMTS)
| Market Cap | 1.26B +8.7% |
| Revenue (ttm) | 83.72M +59.1% |
| Net Income | -148.12M |
| EPS | -3.00 |
| Shares Out | 58.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 240,803 |
| Open | 21.71 |
| Previous Close | 21.56 |
| Day's Range | 21.48 - 23.34 |
| 52-Week Range | 13.25 - 30.00 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 27.71 (+28.05%) |
| Earnings Date | Jul 14, 2026 |
About KMTS
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. The company’s develops and commercializes Cardiac Recovery System platform, a system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. Its platform provides ASSURE WCD, a wearable cardiovert... [Read more]
Financial Performance
In fiscal year 2025, KMTS's revenue was $59.82 million, an increase of 115.05% compared to the previous year's $27.81 million. Losses were -$126.14 million, 25.1% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for KMTS stock is "Strong Buy." The 12-month stock price target is $27.71, which is an increase of 28.05% from the latest price.
News
Kestra Medical Technologies Transcript: Bank of America Global Healthcare Conference 2026
Strong FY 2026 momentum was driven by expanded payer coverage and a larger, more productive sales force, resulting in rapid market share gains and robust revenue growth. Clinical data and innovation are expected to drive further market expansion, margin improvement, and new product launches, with partnerships like Biobeat enhancing future revenue opportunities.
Kestra Medical Technologies to Present at the BofA Securities 2026 Healthcare Conference
KIRKLAND, Wash., April 29, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Showcases Accelerated Innovation at HRS 2026
KIRKLAND, Wash., April 22, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Medical price target lowered to $30 from $32 at BTIG
BTIG lowered the firm’s price target on Kestra Medical (KMTS) to $30 from $32 and keeps a Buy rating on the shares as part of a broader research name on…
Kestra Medical Technologies Named a 2026 USA TODAY Top Workplaces Award Winner
KIRKLAND, Wash., April 09, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Medical files automatic common shares offering
16:35 EDT Kestra Medical (KMTS) files automatic common shares offering
Kestra Medical Technologies Named Finalist for 2026 GeekWire “Deal of the Year”
KIRKLAND, Wash., March 25, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced it has been name...
Kestra Medical Technologies Earnings Call Transcript: Q3 2026
Q3 revenue grew 63% year-over-year to $24.6M, with gross margin up to 52.6% and strong prescription growth. Fiscal 2026 revenue guidance was raised to $93M, and recent payer wins in Florida and the VA are expected to drive further growth and margin expansion.
Kestra Medical Technologies Quarterly report: Q3 2026
Kestra Medical Technologies has published its Q3 2026 quarterly earnings report on March 17, 2026.
Kestra Medical Technologies Earnings release: Q3 2026
Kestra Medical Technologies released its Q3 2026 earnings on March 17, 2026, summarizing the period's financial results.
Kestra Medical Technologies Reports Third Quarter Fiscal 2026 Financial Results
KIRKLAND, Wash., March 17, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today reported financial results...
Kestra Medical Technologies Slides: Company presentation
Kestra Medical Technologies has posted slides in relation to its latest quarterly earnings report, which was published on March 17, 2026.
Kestra Medical Technologies to Report Third Quarter Fiscal 2026 Financial Results on March 17
KIRKLAND, Wash., March 03, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a leading wearable medical device and digital healthcare company, today announced that it will rep...
Kestra Medical price target lowered to $24 from $27 at Goldman Sachs
Goldman Sachs lowered the firm’s price target on Kestra Medical (KMTS) to $24 from $27 and keeps a Neutral rating on the shares. MedTech and Healthcare IT stocks fell sharply…
Kestra Medical Technologies Transcript: 44th Annual J.P. Morgan Healthcare Conference
Kestra is rapidly expanding in an underserved $10B U.S. market, driven by strong clinical results, high patient compliance, and a scalable rental model. Recent innovations, including a partnership with Biobeat for blood pressure monitoring, and robust insurance coverage support continued double-digit growth.
Kestra Medical announces strategic collaboration with Biobeat Technologies
Kestra Medical (KMTS) Technologies announced a strategic collaboration with Biobeat Technologies to expand diagnostic insight for patients prescribed the ASSURE Wearable Cardioverter Defibrillator. Th...
Kestra Medical Technologies Announces Strategic Collaboration with Biobeat Technologies to Expand Diagnostic Insight for Wearable Defibrillator Patients During Cardiac Recovery
KIRKLAND, Wash., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd.
Kestra Medical price target raised to $27 from $25 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Kestra Medical (KMTS) to $27 from $25 and keeps a Neutral rating on the shares. After a year when fundamentals diverged from…
Kestra Medical Technologies to Present at the 44th Annual J.P. Morgan Healthcare Conference
KIRKLAND, Wash., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, is scheduled to present at the 44th Annua...
Kestra Medical price target raised to $25 from $22 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Kestra Medical (KMTS) to $25 from $22 and keeps a Neutral rating on the shares. The company’s Q2 revenue of $22.6 million…
Kestra Medical price target raised to $30 from $28 at Stifel
Stifel raised the firm’s price target on Kestra Medical (KMTS) to $30 from $28 and keeps a Buy rating on the shares. Coming in at the high-end of the company’s…
Kestra Medical price target raised to $28 from $27 at Wells Fargo
Wells Fargo raised the firm’s price target on Kestra Medical (KMTS) to $28 from $27 and keeps an Overweight rating on the shares. The firm notes the company reported Q2…
Kestra Medical price target raised to $30 from $27 at Piper Sandler
Piper Sandler analyst Matt O’Brien raised the firm’s price target on Kestra Medical (KMTS) to $30 from $27 and keeps an Overweight rating on the shares. The firm notes the…
Kestra Medical Technologies Earnings Call Transcript: Q2 2026
Q2 FY26 saw 53% revenue growth and gross margin surpassing 50% for the first time, driven by strong prescription volume, market expansion, and improved in-network mix. Updated guidance raises FY26 revenue to $91M, with continued investments in commercial expansion and clinical evidence supporting further growth.
Kestra Medical Technologies Quarterly report: Q2 2026
Kestra Medical Technologies has published its Q2 2026 quarterly earnings report on December 11, 2025.